US · Healthcare · Biotechnology
EPS came in at -0.42 against a street estimate of -0.45 — a beat of 7.8%.
Analysts rate AgomAb Therapeutics NV American Depositary Shares a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $37.67.
| Fund | Stake |
|---|---|
| EQT Fund Management S.à r.l. | 10.44% |
| Nantahala Capital Management, LLC | 6.37% |
| Sanofi | 5.65% |
| Redmile Group, LLC | 5.55% |
| Cormorant Asset Management, LLC | 5.01% |
| TCG Crossover Management, LLC | 4.17% |
| Federated Hermes Inc | 3.29% |
| Casdin Capital, LLC | 3.15% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AgomAb Therapeutics NV American Depositary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.